Stelara® dosing for crohn’s disease and ulcerative colitis induction dose: a single intravenous infusion using a weight based dosage regimen: 260 mg (weight 55 kg or less), 390 mg (weight more than 55 kg to 85 kg), or 520 mg (weight more than 85 kg). maintenance dose: a subcutaneous 90 mg dose administered 8. For optimal outcome, stelara ® should be dosed and administered as described in the prescribing information. cd=crohn's disease; iv=intravenous; subq=subcutaneous; uc=ulcerative colitis. *approximately 2.2 pounds per kilogram. †induction dose: a single iv infusion using a weight based dosage regimen: stelara ® 260 mg (weight ≤55 kg.
Usual adult dose for crohn's disease acute. initial dose: up to 55 kg: 260 mg iv. greater than 55 kg to 85 kg: 390 mg iv. greater than 85 kg: 520 mg iv. maintenance dose (all weight ranges): 90 mg subcutaneously 8 weeks after the initial dose and every 8 weeks thereafter. comments: the iv infusion should be given over at least 1 hour. We evaluated ustekinumab as 8 week induction therapy and 44 week maintenance therapy in patients with moderate to severe ulcerative colitis. a total of 961 patients were randomly assigned to. Ustekinumab was more effective than placebo for inducing and maintaining remission in patients with moderate to severe ulcerative colitis. (funded by janssen research and devel opment; unifi. Disease and ulcerative colitis . intravenous induction adult dosage regimen . a single intravenous infusion dose of stelara. using the weight based dosage regimen specified in table 3 [see instructions for dilution of stelara ® 130 mg vial for intravenous infusion (2.6)]. table 3: initial intravenous dosage of stelara ® body weight of patient.
Comments are closed.